Quality & complianceOfficial

DKMA flags upcoming IXCHIQ chikungunya vaccine supply problems, expected from end-2026 to end-2028

🇩🇰 DKMA · Mon 02 Nov 2026

Denmark's medicines agency says Valneva Sweden AB's IXCHIQ will face supply difficulties for about two years, citing commercial reasons.

The Danish Medicines Agency (DKMA) has published a supply notice warning of upcoming problems with IXCHIQ, the chikungunya vaccine supplied as powder and solvent for solution for injection by Valneva Sweden AB. The notice is dated 2 November 2026.

DKMA lists the active substance as live attenuated chikungunya virus and the ATC code as J07BP01. The expected period of supply difficulty runs from the end of December 2026 to the end of December 2028.

The agency gives the cause as commercial reasons. The notice does not describe the scale of the shortage, whether supply will be fully interrupted or only constrained, or which alternatives, if any, are available in Denmark.

DKMA directs questions about the current status to the company. The notice appears in the agency's section on supply notices for medicines.

What it means for your team

  • Supply and market-access teams with Danish exposure should plan for possible limited availability of IXCHIQ from the end of December 2026 through the end of December 2028.
  • The notice gives no detail on volumes or alternatives, so contact Valneva Sweden AB directly for current status, as DKMA advises.
  • Regulatory and quality teams should keep monitoring DKMA's supply notices for updates, as the notice may be revised.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Quality & compliance All →